Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

详细信息    查看全文

• 作者：Chieh-Hsin Lin^a ; ^b ; Ping-Kun Chen^a ; ^b ; ^c ; Yue-Cune Chang^e ; Liang-Jen Chuo^d ; Yan-Syun Chen^e ; ^g ; Guochuan E. Tsai^f ; Hsien-Yuan Lane^a ; ^g ; ^{hylane@gmail.com" class="auth_mail}
• 关键词：Alzheimer disease ; clinical trial ; D-amino acids oxidase (DAAO) inhibitor ; mild cognitive impairment ; N-methyl-D-aspartate ; sodium benzoate
• 刊名：Biological Psychiatry
• 出版年：1 May, 2014
• 年：2014
• 卷：75
• 期：9
• 页码：678-685
• 全文大小：227 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background

N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission is vital for learning and memory. Hypofunction of NMDAR has been reported to play a role in the pathophysiology of Alzheimer disease (AD), particularly in the early phase. Enhancing NMDAR activation might be a novel treatment approach. One of the methods to enhance NMDAR activity is to raise the levels of NMDA coagonists by blocking their metabolism. This study examined the efficacy and safety of sodium benzoate, a D-amino acid oxidase inhibitor, for the treatment of amnestic mild cognitive impairment and mild AD.

Methods

We conducted a randomized, double-blind, placebo-controlled trial in four major medical centers in Taiwan. Sixty patients with amnestic mild cognitive impairment or mild AD were treated with 250-750 mg/day of sodium benzoate or placebo for 24 weeks. Alzheimer鈥檚 Disease Assessment Scale-cognitive subscale (the primary outcome) and global function (assessed by Clinician Interview Based Impression of Change plus Caregiver Input) were measured every 8 weeks. Additional cognition composite was measured at baseline and endpoint.

Results

Sodium benzoate produced a better improvement than placebo in Alzheimer鈥檚 Disease Assessment Scale-cognitive subscale (p = .0021, .0116, and .0031 at week 16, week 24, and endpoint, respectively), additional cognition composite (p = .007 at endpoint) and Clinician Interview Based Impression of Change plus Caregiver Input (p = .015, .016, and .012 at week 16, week 24, and endpoint, respectively). Sodium benzoate was well-tolerated without evident side-effects.

Conclusions

Sodium benzoate substantially improved cognitive and overall functions in patients with early-phase AD. The preliminary results show promise for D-amino acid oxidase inhibition as a novel approach for early dementing processes.